Related Experiment Video
Updated: Apr 16, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
How to achieve immune control in chronic hepatitis B?
Margo J H van Campenhout1, Harry L A Janssen
1Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Chronic hepatitis B infection is a global health challenge. Immunomodulatory therapies show promise for controlling or curing the infection by leveraging the host immune system, with HBsAg level monitoring being key.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Chronic hepatitis B remains a significant global health issue.
- Current treatments like nucleos(t)ide analogs and peginterferon-α have limitations in achieving sustainable viral control or cure.
- Hepatitis B virus persists as covalently closed circular DNA in hepatocytes, hindering complete eradication.
Purpose of the Study:
- To explore immunomodulation as a logical approach for controlling or curing chronic hepatitis B.
- To highlight the importance of monitoring HBsAg levels for assessing immune control.
- To introduce the development of new immunomodulatory agents as promising future treatment options.
Main Methods:
- Review of current treatment strategies for chronic hepatitis B.
- Discussion of the role of the host immune system in disease progression.
- Focus on advancements in measuring immune control, including HBsAg level monitoring.
Main Results:
- Treatment-induced HBeAg seroconversion and viral suppression are often unsustainable.
- Loss of HBsAg, a key endpoint, is rarely achieved with current therapies.
- Ongoing research into immunomodulatory agents offers new therapeutic avenues.
Conclusions:
- Immunomodulation is a rational strategy for managing chronic hepatitis B due to the virus-host interaction.
- Monitoring HBsAg levels is crucial for evaluating immune control.
- Emerging immunomodulatory agents represent a promising direction for future hepatitis B treatment.
More Related Videos
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inhibitors of Viral Protein Synthesis
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...